Panel Discussion: Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding

• Exploring the data, targets, and indications investors are prioritizing to support next-generation induced proximity therapeutics
• Discussing funding strategies for early-stage companies, including milestones needed to secure investment and attract pharmaceutical partnerships
• Evaluating how scientific innovation and emerging modalities influence investor confidence and the types of assets and platforms likely to attract investor interest

Speakers:

Phil Chamberlain

Co-Founder, President & Chief Executive Officer

Neomorph

Adam Gilbert

Science Partner

Flagship Pioneering

Venkatesan Raghavan

Executive Director Search and Evaluation - Oncology

Novartis AG

Ryan Potts

Vice President, Research

Amgen Inc.

Jason Kantor

Chief Business Officer

Nurix Therapeutics, Inc.

Elena Diez

Senior Director - External Innovation DPDS

Johnson & Johnson

Carla Bauer

Director, Oncology Search & Evaluation, Business Development & Licensing

Merck & Co

Artavazd Arumov

Principal

Qiming Venture Partners